This study explores the role of charitable drug donation mechanisms in improving the multi-tier healthcare insurance system in China. With socio-economic development and population aging, the growing demand for healthcare necessitates the establishment of a multi-tier healthcare security system as a crucial task of livelihood. Charitable drug donations hold a unique position within this framework, supplementing basic medical insurance coverage, enhancing accessibility to innovative and rare disease drugs, and promoting healthcare equity. In China, such donations primarily operate through collaborations between pharmaceutical enterprises and third-party organizations, employing three models (co-pay, full exemption, and financial aid) across multiple therapeutic areas. Although China's charitable drug donation mechanism has developed relatively mature operation procedures and diversified approaches over two decades of evolution, challenges persist in optimizing operation efficiency and improving the multi-tier healthcare security system. International experience, particularly from the United States (Patient Assistance Programs, PAP) and the United Kingdom (Patient Support Programs, PSP), offers valuable insights regarding donation scope, technical service, and disease course management. This research systematically categorizes seven pharmaceutical donation models while analyzing their applicable scenarios and distinctive characteristics. Meanwhile, it advocates for improvement of laws, policies, and regulatory mechanisms, strengthening organizational capacity building, establishing collaborative mechanisms with basic medical insurance, and enhancing public awareness and participation. These measures aim to fully leverage the supplementary role of charitable drug donations in perfecting China's multi-tier healthcare security system.
Key words
charitable drug donations /
patient assistance programs /
multi-tier healthcare security system /
basic medical insurance
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 郑功成.中国式现代化与多层次医疗保障体系建设[J].学术研究,2023(9):80-86.
[2] 彭韵佳.2023年我国城乡居民大病保险惠及1156万人[EB/OL].(2024-04-03)[2025-02-17].https://www.gov.cn/lianbo/bumen/202404/content_6943480.htm.
[3] 于莹,阎建军.健康保险蓝皮书:中国健康保险发展报告(2023)[M].北京:社会科学文献出版社,2024.
[4] 孙叶竹.数说中国基金会发展之路:中国基金会行业数据发布会[R/OL].(2024-01-15)[2025-02-17].https://ftinews-cms.foundationcenter.org.cn/Uploads/file/20240115/65a4a0a91c769.pdf.
[5] 高蕾.我国共登记认定慈善组织超过1.5万家[EB/OL].(2024-01-15)[2024-10-14].https://www.gov.cn/lianbo/bumen/202410/content_6982357.htm.
[6] 徐鹏航.40年捐助超500万人次中国癌症基金会为癌症防治注入力量[EB/OL].(2024-11-26)[2025-02-17].https://baijiahao.baidu.com/s?id=1816787948878014180&wfr=spider&for=pc.
[7] 民政部.截至6月底全国共有城乡低保对象4037万人[EB/OL].(2024-09-03)[2024-10-14].https://news.cnr.cn/dj/20240903/t20240903_526885744.shtml.
[8] 李欣.从肿瘤药物的慈善赠药谈我国的患者援助项目[J].西部学刊,2022(13):172-176.
[9] 黄伟,陈玉文,史录文.美国药品援助项目对我国药品谈判的启示[J].中国药房,2013,24(05):388-390.
[10] 蒋蓉,孙圆圆,邵蓉.我国药品患者援助项目实施现状与监管制度分析[J].中国药学杂志,2019,54(19):1626-1630.
[11] 中华慈善总会.格列卫患者援助项目[EB/OL].(2020-03-31)[2020-05-31].http://www.chinacharityfederation.org/projectshow/0/13.html.
[12] 诺华制药.诺华患者援助项目[EB/OL].(2024-06-01)[2025-02-17].https://www.novartis.com.cn/novartis-in-china/china-corporate-responsibility/novartis-patient-assistance-program.
[13] 徐婷婷.慈善赠药的是是非非[N].健康时报,2017-08-18(003).
[14] 蒋蓉,葛文霞,邵蓉.制药企业实施药品患者援助项目的行为意愿及影响因素研究[J].中国药房,2020,31(24):2955-2961.
[15] COLLIER EK, PRICE KN, HSIAO JL, et al.Demystifying pharmaceutical patient assistance programs[J].Journal of dermatological treatment,2022,33(1):336-341.
[16] National Conference of State Legislatures.State Pharmaceutical Assistance Programs[EB/OL].(2022-10-26)[2025-02-17].https://www.ncsl.org/health/state-pharmaceutical-assistance-programs.
[17] 蒋蓉,陈童,邵蓉.中美药品患者援助项目实施方式比较研究[J].中国卫生政策研究,2020,13(10):73-79.
[18] 车沛宜.激励企业慈善捐赠的所得税优惠政策研究[D].济南:山东财经大学,2021.
[19] KESSELHEIM AS, AVORN J.Drug companies' patient-assistance programs—helping patients or profits?[J].The New England journal of medicine,2014,370(25):2367-2370.
[20] 美国食品药品监督管理局(FDA).2024年新型药物批准情况[EB/OL].(2525-01-15)[2025-02-17].https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024.
[21] 董雪,顾天成.国产医药工业开启创新“加速跑”[EB/OL].(2024-11-20)[2025-02-17].https://www.gov.cn/yaowen/liebiao/202411/content_6987650.htm.
